TLC-1180

TLC-1180 is a potent, long-acting mitochondrial protonophore in preclinical development by OrsoBio for the treatment of obesity. As a mitochondrial oxidative phosphorylation uncoupler, it increases cellular energy expenditure by dissipating the proton gradient across the mitochondrial membrane, leading to increased metabolic rate and potential weight loss. This mechanism is being explored as a complement to existing obesity therapies such as glucagon-like peptide 1 receptor agonists (GLP-1 RAs). TLC-1180 is designed for weekly oral or subcutaneous administration and aims to preserve lean body mass while enhancing insulin sensitivity and improving lipid profiles in preclinical models[1][2][5].

Other names

TLC 1180TLC1180TLC-1180